

# Brian F Chapin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8725096/publications.pdf>

Version: 2024-02-01

65  
papers

1,275  
citations

430442

18  
h-index

395343

33  
g-index

67  
all docs

67  
docs citations

67  
times ranked

2248  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2835-2842.	0.8	213
2	Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	108
3	Safety of Presurgical Targeted Therapy in the Setting of Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2011, 60, 964-971.	0.9	89
4	Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. <i>European Urology</i> , 2016, 69, 775-787.	0.9	72
5	The use of PET/CT in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 4-21.	2.0	70
6	Can a Durable Disease-Free Survival be Achieved With Surgical Resection in Patients With Pathological Node Positive Renal Cell Carcinoma?. <i>Journal of Urology</i> , 2011, 186, 1236-1241.	0.2	53
7	Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 524-532.	2.0	37
8	Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers. <i>Cancer</i> , 2019, 125, 391-397.	2.0	37
9	The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. <i>BJU International</i> , 2020, 125, 792-800.	1.3	31
10	Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 221-227.	2.0	28
11	Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment. <i>BJU International</i> , 2019, 124, 811-819.	1.3	28
12	Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. <i>BJU International</i> , 2016, 118, 68-76.	1.3	27
13	Role of radical prostatectomy in metastatic prostate cancer: A review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 125-134.	0.8	26
14	Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data. <i>Cancer</i> , 2017, 123, 1617-1624.	2.0	24
15	Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. <i>European Urology</i> , 2021, 79, 298-306.	0.9	24
16	Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. <i>BJU International</i> , 2018, 121, 540-548.	1.3	22
17	Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed?. <i>American Journal of Roentgenology</i> , 2020, 214, 1248-1258.	1.0	22
18	Radical Prostatectomy for Locally Advanced Prostate Cancer: Current Status. <i>Urology</i> , 2015, 86, 10-15.	0.5	21

#	ARTICLE	IF	CITATIONS
19	Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. <i>Cancer</i> , 2020, 126, 506-514.	2.0	21
20	Optimizing the diagnosis and management of ductal prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 337-358.	1.9	21
21	Surgical management of high-risk, localized prostate cancer. <i>Nature Reviews Urology</i> , 2020, 17, 679-690.	1.9	20
22	Influence of Geography on Prostate Cancer Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1286-1295.	0.4	19
23	Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. <i>JAMA Network Open</i> , 2020, 3, e201255.	2.8	18
24	Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. <i>European Urology</i> , 2018, 74, 140-143.	0.9	16
25	Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 130-138.	0.9	14
26	Patterns of metastases of prostatic ductal adenocarcinoma. <i>Cancer</i> , 2020, 126, 3667-3673.	2.0	14
27	Renal Cell Carcinoma: What the Surgeon and Treating Physician Need to Know. <i>American Journal of Roentgenology</i> , 2011, 196, 1255-1262.	1.0	13
28	Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. <i>International Journal of Urology</i> , 2018, 25, 998-1004.	0.5	13
29	Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. <i>BJU International</i> , 2021, 127, 340-348.	1.3	12
30	Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 172-178.	2.0	11
31	Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection. <i>BJU International</i> , 2018, 122, 66-75.	1.3	10
32	Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. <i>BJU International</i> , 2018, 121, 69-76.	1.3	10
33	Impact of CoVID-19 on resident and fellow education: Current guidance and future opportunities for urologic oncology training programs. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 357-364.	0.8	10
34	Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy. <i>Cancer</i> , 2021, 127, 1425-1431.	2.0	10
35	The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer. <i>Future Oncology</i> , 2016, 12, 687-699.	1.1	9
36	Diet quality and Gleason grade progression among localised prostate cancer patients on active surveillance. <i>British Journal of Cancer</i> , 2019, 120, 466-471.	2.9	8

#	ARTICLE	IF	CITATIONS
37	Management of cT4 Prostate Cancer. <i>European Urology Focus</i> , 2020, 6, 221-226.	1.6	8
38	Imaging and Management of Prostate Cancer. <i>Seminars in Ultrasound, CT and MRI</i> , 2020, 41, 207-221.	0.7	8
39	Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort. <i>Cancer</i> , 2021, 127, 720-728.	2.0	7
40	The role of lymph node dissection in renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2011, 16, 186-94.	1.0	6
41	A decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residents. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 13.e19-13.e25.	0.8	6
42	Organizing a clinical trial for the new investigator. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 336-339.	0.8	6
43	Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. <i>Urology</i> , 2020, 138, 91-97.	0.5	6
44	Defining Diagnostic Criteria for Prostatic Ductal Adenocarcinoma at Multiparametric MRI. <i>Radiology</i> , 2022, , 204732.	3.6	6
45	Is Treatment of the Primary Tumor in Metastatic Prostate Cancer Justified?. <i>European Urology</i> , 2014, 65, 1067-1068.	0.9	5
46	Emerging role of cytoreductive prostatectomy in patients with metastatic disease. <i>Translational Andrology and Urology</i> , 2018, 7, S505-S513.	0.6	5
47	Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging. <i>European Urology Oncology</i> , 2019, 2, 257-264.	2.6	5
48	Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. <i>Practical Radiation Oncology</i> , 2020, 10, 282-292.	1.1	5
49	Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. <i>European Journal of Cancer</i> , 2021, 157, 259-267.	1.3	4
50	Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design. <i>European Urology Focus</i> , 2021, 7, 71-77.	1.6	3
51	Contemporary outcomes following robotic prostatectomy for locally advanced and metastatic prostate cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 2178-2187.	0.6	3
52	Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 262-264.	0.2	3
53	Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase. <i>Urology</i> , 2021, 155, 144-151.	0.5	2
54	<sup>18</sup> F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Radiology Imaging Cancer</i> , 2022, 4, e210091.	0.7	2

#	ARTICLE	IF	CITATIONS
55	Reply to Lu Yang, Shi Qiu and Qiang Wei's Letter to the Editor re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol 2016;69:775-787. European Urology, 2017, 71, e51.	0.9	1
56	Can Focal Therapy Replace Radical Therapy for Prostate Cancer? Against Focal Therapy. European Urology Focus, 2017, 3, 524-525.	1.6	1
57	Response to Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. International Journal of Urology, 2018, 25, 1005-1005.	0.5	1
58	Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care. European Urology, 2019, 76, 543-545.	0.9	1
59	Patterns of Care for Prostate Cancer Patients: Predictors of Care, But For Whom?. European Urology, 2017, 71, 738-739.	0.9	0
60	Local Therapy for Disseminated Prostate Cancer: Improved Outcomes or Biased Confounders?. European Urology, 2017, 72, 352-353.	0.9	0
61	Working toward understanding oligo and polymetastatic prostate cancer™. Current Opinion in Urology, 2017, 27, 532.	0.9	0
62	Editorial Comment. Urology, 2019, 131, 174.	0.5	0
63	Clinical Trials in Urology. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 303-304.	0.8	0
64	Research highlights of the 2020 society of urologic oncology young urologic oncologists™ program. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 452-454.	0.8	0
65	Very-high-risk (VHR) localized prostate cancer: an indication for multimodal therapy. Oncotarget, 2019, 10, 1870-1871.	0.8	0